PLC
KYTX icon

Peapod Lane Capital’s Kyverna Therapeutics KYTX Stock Holding History

Peapod Lane Capital’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-40,404
Closed -$336K – 68
2026
Q1 		$336K Sell
40,404
-143,416
-78% -$1.19M 0.28% 61
2025
Q4 		$1.73M Sell
183,820
-134,940
-42% -$1M 1.47% 29
2025
Q3 		$1.91M Sell
318,760
-78,003
-20% -$312K 1.71% 24
2025
Q2 		$1.22M Buy
396,763
+542
+0.1% +$1.34K 1.22% 36
2025
Q1 		$765K Buy
+396,221
New +$1.17M 0.86% 43

Other funds holding KYTX

YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
WB
WesBanco Bank Wheeling, West Virginia $4.02B AUM 32.62% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
EI
Ethic Inc New York $8.02B AUM 45.39% 1-Year Est. Return
SIC
Samalin Investment Counsel Chappaqua, New York $320M AUM 20.87% 1-Year Est. Return
CAI
Capital Advisors Inc Tulsa, Oklahoma $6.8B AUM 26.96% 1-Year Est. Return

Peapod Lane Capital's KYTX Position: Q2 2026 in Review

Peapod Lane Capital sold out of Kyverna Therapeutics (KYTX) in Q2 2026, closing a stake of 40,404 shares — an estimated $336K sold.

Peapod Lane Capital first reported a position in KYTX in Q1 2025 and held it in 5 quarters. The position peaked at $1.91M in Q3 2025. 21 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • Peapod Lane Capital reported no remaining Kyverna Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Peapod Lane Capital sold 40,404 Kyverna Therapeutics shares in Q2 2026, an estimated $336K.
  • Peapod Lane Capital first reported a position in Kyverna Therapeutics in Q1 2025 and held it in 5 quarters.
  • Peapod Lane Capital's Kyverna Therapeutics position peaked at $1.91M in Q3 2025.
  • 21 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Peapod Lane Capital's 13F filing for Q2 2026, filed 27 Jul 2026.